Computational analysis of image-based drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1548-1560

  Brandl, Miriam B ^a,b,c   Pasquier, Eddy ^a,d   Li, Fuhai ^c   Beck, Dominik ^e   Zhang, Sufang ^c   Zhao, Hong ^c   Kavallaris, Maria ^a,e   Wong, Stephen T C ^c  

^a University of New South Wales Sydney   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Metronomics Global Health Initiative   (France)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Compound profiling; High content screening; KSP Eg5 inhibitors; Microtubule targeting agents; Synergy; Triple negative breast cancer

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CYCLOHEXIMIDE; CYTOCHALASIN D; DOXORUBICIN; ISPINESIB; MONASTROL; VINBLASTINE SULFATE; BENZAMIDE DERIVATIVE; KIF11 PROTEIN, HUMAN; KINESIN; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIOKETONE; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; FIBROBLAST; GROWTH INHIBITION; IN VITRO STUDY; MITOSIS INHIBITION; MITOSIS SPINDLE; MOUSE; MOUSE MODEL; NONHUMAN; PREDICTION; SUPPORT VECTOR MACHINE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MITOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; KINESIN; MICE; MICE, INBRED BALB C; MITOSIS; PYRIMIDINES; QUINAZOLINES; THIONES; TRIPLE NEGATIVE BREAST NEOPLASMS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911959806     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.007     Document Type: Article

References (48)

1. Baguley B.C., Kerr D.J. Anticancer Drug Development 2002, Academic Press, San Diego.
2. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
3. Borisy A.A., Elliott P.J., Hurst N.W., Lee M.S., Lehar J., Price E.R., Serbedzija G., Zimmermann G.R., Foley M.A., Stockwell B.R., Keith C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7977-7982.
4. Calzolari D., Bruschi S., Coquin L., Schofield J., Feala J.D., Reed J.C., McCulloch A.D., Paternostro G. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput. Biol. 2008, 4:e1000249.
5. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. - Off. J. Am. Assoc. Cancer Res. 2007, 13:2329-2334.
6. Chabner B., Longo D.L. Cancer chemotherapy and Biotherapy: Principles and Practice 2006, Lippincott Williams & Wilkins, Philadelphia. fourth ed.
7. Chang C.-C., Lin C.-J. LIBSVM: a Library for Support Vector Machines 2001.
8. Chou T.C., Hayball M.P. CalcuSyn Version 2.1: Windows Software for Dose Effect Analysis 1996, Biosoft, Cambridge, UK.
9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
10. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 2006, 5:649-659.
11. Enomoto T. Microtubule disruption induces the formation of actin stress fibers and focal adhesions in cultured cells: possible involvement of the rho signal cascade. Cell Struct. Func. 1996, 21:317-326.
12. Gartner M., Sunder-Plassmann N., Seiler J., Utz M., Vernos I., Surrey T., Giannis A. Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5. Chembiochem 2005, 6:1173-1177.
13. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., Harris L., Hait W., Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J.Clin. Oncol. - Off. J. Am. Soc. Clin. Oncol. 2006, 24:5652-5657.
14. Hartman J.L.t., Garvik B., Hartwell L. Principles for the buffering of genetic variation. Science 2001, 291:1001-1004.
15. Jackson J.R., Patrick D.R., Dar M.M., Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat. Rev. Cancer 2007, 7:107-117.
16. Jia J., Zhu F., Ma X., Cao Z., Li Y., Chen Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8:111-128.
17. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
18. Kitano H. Biological robustness. Nat. Rev. Gen. 2004, 5:826-837.
19. Kitano H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 2007, 6:202-210.
20. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., Lee M.S., Zimmermann G.R., Borisy A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
21. Leizerman I., Avunie-Masala R., Elkabets M., Fich A., Gheber L. Differential effects of monastrol in two human cell lines. Cell Mol. Life Sci. 2004, 61:2060-2070.
22. Li F., Zhou X., Ma J., Wong S.T. An automated feedback system with the hybrid model of scoring and classification for solving over-segmentation problems in RNAi high content screening. J.Microsc. 2007, 226:121-132.
23. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G.N., Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J.Clin. Oncol. - Off. J. Am. Soc. Clin. Oncol. 2008, 26:1275-1281.
24. Loo L.-H., Wu L.F., Altschuler S.J. Automated multivariate profiling of drug effects from fluorescence microscopy images. 3rd IEEE International Symposium on Biomedical Imaging: Nano to Macro, 2006 2006, 251-254.
25. Loo L.H., Wu L.F., Altschuler S.J. Image-based multivariate profiling of drug responses from single cells. Nat. Methods 2007, 4:445-453.
26. Mayer L.D., Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 2007, 7:216-223.
27. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286:971-974.
28. Megason S.G., Fraser S.E. Imaging in systems biology. Cell 2007, 130:784-795.
29. Miller K., Ng C., Ang P., Brufsky A.M., Lee S.C., Dees E.C., Piccart M., Verrill M., Wardley A., Loftiss J., Bal J., Yeoh S., Hodge J., Williams D., Dar M., Kathman S., Ho P.T.C. Phase II, open label study of SB-715992 (ispinesib) in subjects with advanced or metastatic breast cancer. 28th Annual San Antonio Breast Cancer Symposium, San Antonio (TX) 2005.
30. Nelander S., Wang W., Nilsson B., She Q.B., Pratilas C., Rosen N., Gennemark P., Sander C. Models from experiments: combinatorial drug perturbations of cancer cells. Mol. Syst. Biol. 2008, 4:216.
31. Ngan V.K., Bellman K., Hill B.T., Wilson L., Jordan M.A. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Molecular Pharmacology 2001, 60:225-232.
32. Ocana A., Amir E., Yeung C., Seruga B., Tannock I.F. How valid are claims for synergy in published clinical studies?. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol./ESMO 2012, 23:2161-2166.
33. Ospovat I., Siegelmann-Danieli N., Grenader T., Hubert A., Hamburger T., Peretz T. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Tumori 2009, 95:683-686.
34. Pasquier E., Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008, 60:165-170.
35. Pasquier E., Sinnappan S., Munoz M.A., Kavallaris M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol. Cancer Ther. 2010, 9:1408-1418.
36. Pritchard J.R., Bruno P.M., Gilbert L.A., Capron K.L., Lauffenburger D.A., Hemann M.T. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E170-E179.
37. Purcell J.W., Davis J., Reddy M., Martin S., Samayoa K., Vo H., Thomsen K., Bean P., Kuo W.L., Ziyad S., Billig J., Feiler H.S., Gray J.W., Wood K.W., Cases S. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin. Cancer Res. - Off. J. Am. Assoc. Cancer Res. 2010, 16:566-576.
38. Ramaswamy S. Rational design of cancer-drug combinations. N.Engl. J. Med. 2007, 357:299-300.
39. Rath O., Kozielski F. Kinesins and cancer. Nat. Rev. Cancer 2012, 12:527-539.
40. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
41. Rodon J., Till E., Patnaik A., Takimot C., Kathmanz S., Williams D., Vasist L., Bowen C., Hodge J., Dar M., Tolcher A. Phase I study of lspinesib in combination with capecitabine in patients with advanced solid tumors. 8th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic 2006.
42. Sarli V., Huemmer S., Sunder-Plassmann N., Mayer T.U., Giannis A. Synthesis and biological evaluation of novel EG5 inhibitors. Chembiochem 2005, 6:2005-2013.
43. Simmons J.K., Patel J., Michalowski A., Zhang S., Wei B.-R., Sullivan P., Gamache B., Felsenstein K., Kuehl W.M., Simpson R.M., Zingone A., Landgren O., Mock B.A. TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol. Oncol. 2014, 8:261-272.
44. Uematsu Y., Kogo Y., Ohishi I. Disassembly of actin filaments by botulinum C2 toxin and actin-filament-disrupting agents induces assembly of microtubules in human leukaemia cell lines. Biol. Cell 2007, 99:141-150.
45. Wang J., Zhou X., Li F., Bradley P.L., Chang S.F., Perrimon N., Wong S.T. An image score inference system for RNAi genome-wide screening based on fuzzy mixture regression modeling. J.Biomed. Inform. 2009, 42:32-40.
46. Wong P.K., Yu F., Shahangian A., Cheng G., Sun R., Ho C.M. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5105-5110.
47. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.
48. Zinner R.G., Barrett B.L., Popova E., Damien P., Volgin A.Y., Gelovani J.G., Lotan R., Tran H.T., Pisano C., Mills G.B., Mao L., Hong W.K., Lippman S.M., Miller J.H. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol. Cancer Therap. 2009, 8:521-532.